A week later, Abraham woke up in the middle of the night and tried to stand. She collapsed to the floor, struggling to ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with tanruprubart at a dose of 30 mg/kg recovered to a healthy state with a score of 0 or ...

To beef up its case for tanruprubart, Annexon also announced on Wednesday that a real-world study of the drug likewise showed a “rapid increase in muscle strength” versus current standards of care in ...

23 LUG - La sindrome di Guillain-Barré (GBS) sarà aggiunta alla lista degli effetti indesiderati del vaccino Janssen (Johnson & Johnson) Covid-19 con frequenza molto rara e sarà inserita un ...